COMPANY

NeuroTrauma Sciences

HQ: Alpharetta, GA source · neurotraumasciences.com ↗ · Southeast

Location: Alpharetta, GA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Acute Ischemic Stroke NTS-521

Timeline

Oct 31, 2026 Trial start 2: A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic source ↗
May 1, 2023 Trial start Phase 1: Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults source ↗

Dec 15, 2028 (ESTIMATED) · 2 · A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Str · NCT07742098

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07742098	A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke	2	Not yet recruiting	Oct 31, 2026	Dec 15, 2028 (estimated)
NCT05547438	Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults	Phase 1	Terminated	May 1, 2023	Dec 18, 2023 (actual)